上莱茵生物技术有限公司获得250万瑞士法郎种子轮融资，加速生物技术和食品创新领域的全球扩张-动脉网

Oberland Biotech GmbH Secures CHF 2.5 Million Seed Funding Round to Accelerate Global Expansion in Biotechnology and Food Innovation

CISION 等信源发布 2026-05-01 15:00



可切换为仅中文







ZUG, Switzerland

楚格，瑞士

，

May 1, 2026

2026年5月1日

/PRNewswire/ -- Oberland Biotech GmbH, a biotechnology and nutritional food company operating internationally, today announced the successful completion of a CHF 2.5 million seed funding round through a convertible instrument.

/PRNewswire/ -- 国际运营的生物技术和营养食品公司Oberland Biotech GmbH今日宣布，通过可转换工具成功完成了250万瑞士法郎的种子轮融资。

The round was supported by 999 Family Office Pte. Ltd, acting under the supervision of its lead investor.

本轮融资由999家族办公室有限公司在其主要投资者的监督下支持。

继续阅读

Oberland Biotech Logo

奥伯兰生物技术标志

999 Family Office Logo

999家族办公室标志

Oberland Biotech focuses on the trade, sale, and export of nutritional supplements and food products across Switzerland and international markets. The company also engages in strategic collaborations, establishes subsidiaries and branches globally, and participates in projects within the food, nutrition, and biotechnology sectors..

上陆生物技术公司专注于在瑞士和国际市场贸易、销售和出口营养补充剂及食品。该公司还参与战略协作，在全球范围内建立子公司和分支机构，并参与食品、营养和生物技术领域的项目。

This new financing will enable Oberland Biotech to further accelerate its development across key strategic areas, including product development, international expansion, recruitment, and marketing and sales growth.

这项新的融资将使奥伯兰生物技术公司能够进一步加快其在产品开发、国际扩张、招聘以及市场营销和销售增长等关键战略领域的发展。

Strategic Expansion

战略性扩张

The company intends to strengthen its global presence, with a particular focus on the United States and Asian markets, while continuing to build scalable operations in the broader international biotechnology and nutrition ecosystem.

公司打算加强其全球影响力，特别关注美国和亚洲市场，同时继续在更广泛的国际生物技术和营养生态系统中建立可扩展的运营。

Leadership Commentary

领导力评论

'This funding marks an important milestone for Oberland Biotech as we accelerate our mission to develop and scale innovative solutions in the food and biotechnology sector. With the support of our investor, we are well positioned to expand internationally and strengthen our product pipeline,' said Phillip Josef Jancer, CEO and Founder of Oberland Biotech GmbH..

“这笔资金标志着Oberland Biotech的一个重要里程碑，因为我们正在加速推进在食品和生物技术领域开发和扩展创新解决方案的使命。在投资者的支持下，我们已为国际扩张和加强产品管线做好了充分准备，” Oberland Biotech GmbH首席执行官兼创始人Phillip Josef Jancer表示。

'I would also like to sincerely thank the entire team at 999 Family Office Pte. Ltd, and in particular Mr. Raghun Kataria, their CFO, for their trust, support, and guidance throughout this process.'

“我还要衷心感谢999家族办公室私人有限公司的整个团队，特别是他们的首席财务官拉古恩·卡塔里亚先生，在整个过程中给予的信任、支持和指导。”

About Oberland Biotech GmbH

关于奥伯兰德生物科技有限公司

Oberland Biotech GmbH is a biotechnology and food-focused company engaged in the trade, sale, and export of nutritional supplements and food products internationally. The company develops and participates in projects within the food, nutrition, and biotechnology sectors and maintains a flexible structure to support long-term global growth..

奥伯兰生物技术有限公司是一家专注于生物技术和食品的公司，从事营养补充剂和食品的国际贸易、销售和出口。公司开发并参与食品、营养和生物技术领域的项目，并保持灵活的结构以支持长期的全球增长。

Oberland Biotech Contact:

奥伯兰生物技术联系方式：

[email protected]

电子邮件地址

www.oberlandbiotech.com

About 999 Family Office Pte. Ltd

关于999家族办公室私人有限公司

999 Family Office Pte. Ltd is an investment family office active in supporting innovative companies across multiple sectors.

999家族办公室有限公司是一家投资家族办公室，活跃于支持跨多个行业的创新公司。

999 Family Office Contact:

999家族办公室联系方式：